Barclays raised the firm’s price target on Avantor to $27 from $24 and keeps an Overweight rating on the shares. The company reported a strong Q4 and conservative 2024 guidance that sets the business up for a “beat/raise opportunity” once the bioprocessing recovery kicks in, the analyst tells investors in a research note. The firm sees upside to margins coming from cost-outs.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVTR:
- Avantor Is Worried About This – Should You Be Worried Too?
- Avantor Inc Announces Segment Realignment and Recast Financials
- Avantor® Reports Fourth Quarter and Full Year 2023 Results
- AVTR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Avantor put volume heavy and directionally bearish
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue